ASP Isotopes (NASDAQ:ASPI) COO Robert Ainscow Sells 22,500 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 22,500 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $2.11, for a total transaction of $47,475.00. Following the transaction, the chief operating officer owned 2,225,941 shares of the company’s stock, valued at $4,696,735.51. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Tuesday, September 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The stock was sold at an average price of $4.29, for a total transaction of $36,199.02.
• On Wednesday, September 2nd, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The shares were sold at an average price of $3.90, for a total transaction of $97,500.00.

ASP Isotopes Stock Down 3.7%

Shares of NASDAQ ASPI opened at $2.06 on Tuesday. The firm’s 50-day moving average is $3.35 and its two-hundred day moving average is $4.71. The company has a market capitalization of $315.82 million, a PE ratio of -1.56 and a beta of 3.69. ASP Isotopes Inc. has a 12-month low of $1.89 and a 12-month high of $11.22. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%. The business had revenue of $5.12 million for the quarter, compared to analysts’ expectations of $4.47 million.

Institutional Investors Weigh In On ASP Isotopes

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of ASP Isotopes in the second quarter valued at approximately $57,331,000. Encompass Capital Advisors LLC purchased a new position in shares of ASP Isotopes during the first quarter valued at approximately $30,551,000. AWM Investment Company Inc. purchased a new position in shares of ASP Isotopes during the second quarter valued at approximately $9,837,000. Philadelphia Financial Management of San Francisco LLC acquired a new stake in ASP Isotopes during the second quarter worth approximately $8,353,504. Finally, Man Group plc acquired a new stake in ASP Isotopes during the second quarter worth approximately $5,153,000. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday, September 21st. Wall Street Zen raised ASP Isotopes from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc (NASDAQ: ASPI) is a development-stage advanced materials company focused on isotope enrichment. The company is developing proprietary technology intended to separate and enrich isotopes for use in several high-value markets, including nuclear energy, medicine, semiconductors, quantum computing and other industrial applications.

ASP Isotopes has described its platform as being designed to provide more efficient and scalable isotope production than certain conventional enrichment methods.